Is NVO stock a Buy, Sell, or Hold?

Based on our analysis, NVO is currently a WAIT with low confidence. 📊 MIXED SIGNALS: NVO shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of NVO stock?

Our analysis estimates the fair value range for NVO to be between $39.27 and $46.34. The current price is $37.32.

What is the analyst price target for NVO?

The average Wall Street analyst price target for NVO is $45.80. This implies a potential upside of 22.7% from current levels.

Novo-Nordisk A/S (NVO) Stock: Buy, Sell, or Hold?

NVO - Novo-Nordisk A/S

Pharmaceutical Preparations

$37.32

-0.08 (-0.21%) ▼

5d: -3.81%

30d: -20.21%

90d: -24.24%

WAIT

LOW Confidence

Protect Your NVO Gains

Analysis Updated: Oct 2, 2026 12:00 AM ET

Earnings: Nov 04, 2026

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Oct 2, 2026 at $37.32 · last confirmed Oct 2, 2026

Strength: 8.1/10

Get Alerted When NVO Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: NVO shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: -3.1%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$47.26

Based on 0.5% avg growth

INTRINSIC VALUE TODAY

$29.35

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.1x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: NVO is currently trading at $37.32, which is considered oversold relative to its 30-day fair value range of $39.27 to $46.34. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.7) compared to its historical average (2.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.5% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, NVO is in a strong downtrend. The price is currently testing key support at $37.17. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.80 (+22.7%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $39.27 - $46.34

Company Quality Score 45/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 79.5%

Protect Your Profits

Holding NVO? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (45/100)
BULLISH: High volume confirmation
BULLISH: Trading 22.7% below Wall St target ($45.80)
WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $39.27 - $46.34

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $37.17

Resistance Level $41.17

Current Trend Strong Downtrend

Technical data as of Oct 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 1.69

Wall Street Target $45.80 (+22.7%)

Revenue Growth (YoY) 2.1%

Earnings Growth (YoY) -20.6%

Profit Margin 35.4%

Valuation Discount vs History -6.5% cheaper

PE vs Historical 1.7 vs 2.1 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -6.5% (market-implied from PE analysis)

1-Year Target $34.89 (-7%)

2-Year Target $32.63 (-13%)

3-Year Target $30.51 (-18%)

3-Yr Target (if PE normalizes) (PE: 2→2) $37.83 (+1%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.4, Growth: -3.1%) $409.04 (+996%)

Base: (SPY PE: 1.7, Growth: -3.1%) $33.95 (-9%)

Bear: (PE: 1.4, Growth: -3.1%) $28.86 (-23%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (2x PE) as earnings recover.

Trailing PE: 9.49 | Current EPS (TTM): $3.94

Bull Case $82.28 (+121%)

Analyst growth 100.0%, PE expands to 10.4

Base Case $74.80 (+100%)

Market implied 100.0%, PE stable at 9.5

Bear Case $25.43 (-32%)

Severe decline -20.0%, PE contracts to 8.1

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 1.7 to 2.1

Stabilization Target: $46.29 (+24.0%)

PE Expansion Potential: +24.0%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 03, 2026 11:33 AM ET
Data refreshes hourly during market hours. Next update: 12:33 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is NVO showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for NVO.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1325	48 HOLD
GILD Gilead Sciences Inc	BUY 30 analysts	$159	46 HOLD
ABBV AbbVie Inc	BUY 28 analysts	$279	57 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$389	55 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$238	48 HOLD

LLY Eli Lilly and Com…

48 HOLD

GILD Gilead Sciences I…

Advanced NVO Option Strategies

Professional options setups generated by AI based on today's NVO price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for NVO

NVO Technical Chart NVO Price Prediction NVO Earnings Date NVO Investment Advisor NVO Fair Price Analyzer NVO Options Advisor NVO Options Chain NVO Options Analysis NVO Competitors

Compare NVO with Peers

NVO vs LLY
Which one to buy?

NVO vs UNH
Which one to buy?

NVO vs ASML
Which one to buy?

NVO vs SMCI
Which one to buy?

NVO vs HIMS
Which one to buy?

GOVX vs NVO
Winner: Tie

ELVN vs NVO
Winner: Tie

RNAC vs NVO

LPCN vs NVO

GHRS vs NVO
Winner: Tie

NVO vs UNH

NVO vs HIMS
Winner: Tie

CLNNW vs NVO

NVO vs LLY

ALTS vs NVO

Create New Comparison View All Competitors

Tradestie